

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL                                    |           |
|---|-----------|
| OMB Number:                                     | 3235-0287 |
| Estimated average burden<br>hours per response: | 0.5       |

☐

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☐

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|   |  |   |
|---|--|---|
| 1. Name and Address of Reporting Person*<br><u>DUGGAN ROBERT W</u><br><br>(Last) (First) (Middle)<br><u>C/O SUMMIT THERAPEUTICS INC.</u><br><u>601 BRICKELL KEY DRIVE SUITE 1000</u><br><br>(Street)<br><u>MIAMI</u> <u>FL</u> <u>33131</u><br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>Summit Therapeutics Inc.</u> [ <u>SMMT</u> ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br><br><input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner<br><br><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)<br><br><u>Co-Chief Executive Officer</u> |
|   | 3. Date of Earliest Transaction (Month/Day/Year)<br><u>05/30/2025</u>                          |   |
|   | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                       | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br><br>Form filed by More than One Reporting Person   |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4)                                   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|--------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price  |   |  |   |
| Common Stock                    | 05/30/2025                           |  | M <sup>(1)</sup>               |   | 74,545  | A          | \$2.64 | 555,754,696   | D  |   |
| Common Stock                    |                                      |  |                                |   |   |            |        | 31,000 <sup>(2)</sup>   | I  | By Spouse   |
| Common Stock                    |                                      |  |                                |   |   |            |        | 10,199,776 <sup>(2)</sup>   | I  | By the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee |
| Common Stock                    |                                      |  |                                |   |   |            |        | 25,457,666 <sup>(2)</sup>   | I  | By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee  |
| Common Stock                    |                                      |  |                                |   |   |            |        | 50,000 <sup>(2)</sup>   | I  | Immediate family member of Spouse   |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |        | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |                            | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|--------|--|-----------------|---|----------------------------|--|--|---|--|
|  |  |                                      |  | Code                           | V | (A)  | (D)    | Date Exercisable   | Expiration Date | Title   | Amount or Number of Shares |  |  |   |  |
| Stock Option (right to buy)                | \$2.64   | 05/30/2025                           |  | M <sup>(1)</sup>               |   |  | 74,545 | <sup>(3)</sup>   | 01/02/2034      | Common Stock  | 74,545                     | \$0  | 0  | D   |  |

Explanation of Responses:

1. On May 30, 2025, the Reporting Person exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of \$2.64 per share. The Reporting Person did not sell the underlying shares.
2. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
3. The option was granted on January 2, 2024. The shares underlying the option vested in four equal quarterly installments on March 31, June 30, September 30 and December 31, 2024.

Remarks:

/s/ Robert W. Duggan  
\*\* Signature of Reporting Person

06/02/2025  
Date

**\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).**  
**Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.**

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**